Why the study?
Paclitaxel is commonly used for various carcinomas, but paclitaxel-induced myocardial infarction is a rare and life-threatening adverse effect.
Highlights the rare but life-threatening risk of paclitaxel-induced myocardial infarction, particularly in patients with pre-existing coronary artery disease risk factors.
Paclitaxel may precipitate MI in high-risk CAD patients; leaves open need for prospective cardiotoxicity surveillance studies.
Background: Paclitaxel is a chemotherapeutic agent commonly used for ovarian, lung, breast carcinoma, and Kaposi’s sarcoma. Its common side effects include hypersensitivity reaction, bone marrow suppression, and peripheral neuropathy. However, a rare and life-threatening side effect is paclitaxel-induced myocardial infarction. Case presentation: A man in his 70s with type 2 diabetes mellitus, hypertension, heavy smoking history, previous coronary artery disease with stent in left anterior descending artery (LAD), and non-small lung cancer presented with non-ST elevation myocardial infarction during infusion of paclitaxel infusion. Coronary angiogram showed de novo three vessel disease with 70% stenosis in ostial to distal left main artery (LM) and 80% in-stent re-stenosis in proximal to mid left anterior descending artery. Conclusions: Physicians should be keeping this in mind when dealing with patients on paclitaxel, especially if they have previous risk factors for coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: